Accelerant's Exchange platform is driving explosive top-line growth, with Q2 2026 revenue surging 74.8% year-over-year and the combined ratio improving to a profitable 83.4%. However, this rapid expansion is accompanied by significant operational risks, includ...
Price trend, volume and key moving averages
Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | $0.32+96.4% vs $0.16 | $357M+27.8% vs $279M |
Q2 2026 May 13, 2026 | $0.17+6.3% vs $0.16 | $273M+11.8% vs $245M |
Q2 2026 Mar 18, 2026 | $0.23+43.8% vs $0.16 | $248M-1.6% vs $252M |
Q4 2025 Nov 12, 2025 | $0.38+75.9% vs $0.22 | $267M+5.5% vs $253M |
Accelerant (NYSE: ARX - Get Free Report) and Hagerty (NYSE: HGTY - Get Free Report) are both mid-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership. Valuation and Earnings This table compares Accelerant and Hagerty"s
ATLANTA--(BUSINESS WIRE)--Accelerant Announces Expiration of “Go-Shop” Period.
Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 15, 2026Insiders may stand to receive substantial financial benefits
Accelerant Holdings NYSE: ARX jumped into view for investors in mid-August after its shares surged 43% in a single day. This type of share price leap is often reserved for clinical-stage biotech firms announcing breakthrough results, for instance, not for an unglamorous firm connecting specialty insurance risk across a network of capital providers.
Benchmark ARX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Accelerant Holdings (ARX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.73 | $4.31B | -2.63 | 47.15% | -153.96% | -234.8% | — | |
| $334.53 | $7.62B | 15.45 | 18.04% | 28.49% | 29.06% | — | |
| $38.39 | $10.69B | 81.68 | 21.28% | 5.84% | 15.93% | — | |
| $94.26 | $32.93B | 8.11 | 14.27% | 24.44% | 19.52% | — | |
| $322.99 | $13.42B | 5.70 | 9.45% | 24.71% | 13.88% | — | |
| $181.39 | $2.32B | 7.29 | 20.21% | 32.6% | 28.69% | — |
Accelerant Holdings (ARX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Accelerant Holdings (ARX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 13, 2026·SEC
May 29, 2026·SEC
Mar 18, 2026·SEC
Get notified when ARX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Accelerant Holdings (ARX) stock FAQ — growth, dividends, profitability & financials explained
Accelerant Holdings (ARX) grew revenue by 47.1% over the past year. This is strong growth.
Accelerant Holdings (ARX) reported a net loss of $1.30B for fiscal year 2025.
Accelerant Holdings (ARX) has a return on equity (ROE) of -234.8%. Negative ROE indicates the company is unprofitable.
Accelerant Holdings (ARX) has a combined ratio of 250.3%. A ratio above 100% means claims and expenses exceed premiums.
